Literature DB >> 15093585

Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells.

T Asklund1, I B Appelskog, O Ammerpohl, T J Ekström, P M Almqvist.   

Abstract

Human glioblastoma cell cultures were established and the expression of glial fibrillary acidic protein (GFAP) and the gap-junction protein connexin 43 (Cx43) was confirmed by Western blot. Following treatment with 4-phenylbutyrate (4-PB), increased concentrations of non-phosphorylated GFAP were seen, while phosphorylated isoforms remained intact. Immunocytochemical staining of glioblastoma cells revealed an intracellular redistribution of GFAP. In addition to cytoplasmic immunostaining, GFAP immunoreactivity was also associated with the nucleus and/or the nuclear membrane. Phosphorylated and non-phosphorylated Cx43 proteins were increased 2- to 5-fold following 4-PB treatment, and were redistributed to areas of the cell surface, participating in cell-to-cell contacts. In addition, functional gap-junction coupling was amplified, as indicated by increased fluorescent dye transfer, and elevated levels of Cx43 protein were detected in parallel with enhanced gap-junction communication. Induced cell differentiation, with improved functional coupling of tumour cells, may be of importance for therapeutic strategies involving intercellular transport of low molecular-weight compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15093585     DOI: 10.1016/j.ejca.2003.11.034

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

Review 1.  Post-translational modifications of nucleosomal histones in oligodendrocyte lineage cells in development and disease.

Authors:  Siming Shen; Patrizia Casaccia-Bonnefil
Journal:  J Mol Neurosci       Date:  2008-05       Impact factor: 3.444

Review 2.  Epigenetic mechanisms facilitating oligodendrocyte development, maturation, and aging.

Authors:  Sjef Copray; Jimmy Long Huynh; Falak Sher; Patrizia Casaccia-Bonnefil; Erik Boddeke
Journal:  Glia       Date:  2009-11-15       Impact factor: 7.452

3.  Cardiac cellular coupling and the spread of early instabilities in intracellular Ca2+.

Authors:  Zhiheng Jia; Harold Bien; Yohannes Shiferaw; Emilia Entcheva
Journal:  Biophys J       Date:  2012-03-20       Impact factor: 4.033

Review 4.  Chaperone proteins and brain tumors: potential targets and possible therapeutics.

Authors:  Michael W Graner; Darell D Bigner
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

5.  Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells.

Authors:  Bo Gong; Li-Yun Zhang; Dennis Shun-Chiu Lam; Chi-Pui Pang; Gary Hin-Fai Yam
Journal:  Mol Vis       Date:  2010-06-04       Impact factor: 2.367

6.  Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy.

Authors:  Sylvine Cottin; Karim Ghani; Pedro Otavio de Campos-Lima; Manuel Caruso
Journal:  Mol Cancer       Date:  2010-06-10       Impact factor: 27.401

7.  ERp29 restricts Connexin43 oligomerization in the endoplasmic reticulum.

Authors:  Shamie Das; Tekla D Smith; Jayasri Das Sarma; Jeffrey D Ritzenthaler; Jose Maza; Benjamin E Kaplan; Leslie A Cunningham; Laurence Suaud; Michael J Hubbard; Ronald C Rubenstein; Michael Koval
Journal:  Mol Biol Cell       Date:  2009-03-25       Impact factor: 4.138

8.  Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.

Authors:  Chandra M Das; Dolly Aguilera; Hernan Vasquez; Preethi Prasad; Ming Zhang; Johannes E Wolff; Vidya Gopalakrishnan
Journal:  J Neurooncol       Date:  2007-05-30       Impact factor: 4.130

Review 9.  Epigenetics of neural repair following spinal cord injury.

Authors:  Elisa M York; Audrey Petit; A Jane Roskams
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 10.  Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.

Authors:  Pavel Bezecny
Journal:  Med Oncol       Date:  2014-05-18       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.